Sangamo Therapeutics, Inc. (SGMO)

Market Cap	104.18M
Revenue (ttm)	176.23M
Net Income (ttm)	-257.83M
Shares Out	203.67M
EPS (ttm)	-1.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,022,430
Open	0.479
Previous Close	0.485
Day's Range	0.470 - 0.529
52-Week Range	0.290 - 1.780
Beta	1.35
Analysts	Buy
Price Target	4.64 (+807.14%)
Earnings Date	May 3, 2024

About SGMO

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of imm...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 6, 2000
• Employees: 405
• Stock Exchange: NASDAQ
• Ticker Symbol: SGMO

Financial Performance

In 2023, SGMO's revenue was $176.23 million, an increase of 58.34% compared to the previous year's $111.30 million. Losses were -$257.83 million, 34.1% more than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for SGMO stock is "Buy." The 12-month stock price forecast is $4.64, which is an increase of 807.14% from the latest price.

Price Target

$4.64

(807.14% upside)

Analyst Consensus: Buy